20 148
[76]
Yaxley JW, Coughlin GD, Chambers SK, et al. Robot-assisted lapa- roscopic prostatectomy versus open radical retropubic prostatec- tomy: early outcomes from a randomised controlled phase 3 study. Lancet 2016;388:1057–66.
[77]
Hu JC, Gandaglia G, Karakiewicz PI, et al. Comparative effective- ness of robot-assisted versus open radical prostatectomy cancer control. Eur Urol 2014;66:666–72.[78]
Pearce SM, Pariser JJ, Karrison T, Patel SG, Eggener SE. Comparison of perioperative and early oncologic outcomes between open and robotic assisted laparoscopic prostatectomy in a contemporary population based cohort. J Urol 2016;196:76–81.
[79]
Hu JC, O’Malley P, Chughtai B, et al. Comparative effectiveness of cancer control and survival after robot-assisted versus open radi- cal prostatectomy. J Urol 2017;197:115–21.[80]
O’Neil B, Koyama T, Alvarez J, et al. The comparative harms of open and robotic prostatectomy in population based samples. J Urol 2016;195:321–9.
[81]
Barry MJ, Gallagher PM, Skinner JS, Fowler Jr FJ. Adverse effects of robotic-assisted laparoscopic versus open retropubic radical pros- tatectomy among a nationwide random sample of medicare-age men. J Clin Oncol 2012;30:513–8.
[82]
Eastham JA, Kattan MW, Riedel E, et al. Variations among indi- vidual surgeons in the rate of positive surgical margins in radical prostatectomy specimens. J Urol 2003;170:2292–5.
[83]
Hu JC, Gold KF, Pashos CL, Mehta SS, Litwin MS. Role of surgeon volume in radical prostatectomy outcomes. J Clin Oncol 2003;21: 401–5.[84]
Almatar A, Wallis CJ, Herschorn S, et al. Effect of radical prosta- tectomy surgeon volume on complication rates from a large population-based cohort. Can Urol Assoc J 2016;10:45–9.[85]
Michl U, Tennstedt P, Feldmeier L, et al. Nerve-sparing surgery technique, not the preservation of the neurovascular bundles, leads to improved long-term continence rates after radical pros- tatectomy. Eur Urol 2016;69:584–9.[86]
Schlomm T, Tennstedt P, Huxhold C, et al. Neurovascular structure-adjacent frozen-section examination (NeuroSAFE) increases nerve-sparing frequency and reduces positive surgical margins in open and robot-assisted laparoscopic radical prosta- tectomy: experience after 11,069 consecutive patients. Eur Urol 2012;62:333–40.[87]
Nguyen PL, Gu X, Lipsitz SR, et al. Cost implications of the rapid adoption of newer technologies for treating prostate cancer. J Clin Oncol 2011;29:1517–24.
[88]
Zaorsky NG, Shaikh T, Murphy CT, et al. Comparison of outcomes and toxicities among radiation therapy treatment options for prostate cancer. Cancer Treat Rev 2016;48:50–60.[89]
Zelefsky MJ, Levin EJ, Hunt M, et al. Incidence of late rectal and urinary toxicities after three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for localized prostate can- cer. Int J Radiat Oncol Biol Phys 2008;70:1124–9.[90]
Kuban DA, Levy LB, Cheung MR, et al. Long-term failure patterns and survival in a randomized dose-escalation trial for prostate cancer. Who dies of disease? Int J Radiat Oncol Biol Phys 2011;79: 1310–7.[91]
Michalski JM, Moughan J, Purdy J, et al. A randomized trial of 79.2 G y versus 70.2 Gy radiation therapy (RT) for localized pros- tate cancer. J Clin Oncol 2015;33(7 Suppl):4.[92]
Dearnaley DP, Sydes MR, Graham JD, et al. Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial. Lancet Oncol 2007;8:475–87.[93] Zaorsky NG, Keith SW, Shaikh T, et al. Impact of radiation therapy
dose escalation on prostate cancer outcomes and toxicities. Am J
Clin Oncol, e-published 2016 Mar 24. In press.
http://dx.doi.org/ 10.1097/COC.0000000000000285 .[94]
Kuban DA, Tucker SL, Dong L, et al. Long-term results of the M.D. Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys 2008;70:67–74.[95]
Dearnaley D, Syndikus I, Mossop H, et al. Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferi- ority, phase 3 CHHiP trial. Lancet Oncol 2016;17:1047–60.[96]
Incrocci L, Wortel RC, Alemayehu WG, et al. Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO): final efficacy results from a randomised, multicentre, open-label, phase 3 trial. Lancet Oncol 2016;17:1061–9.
[97]
Oliai C, Bernetich M, Brady L, et al. Propensity score matched comparison of SBRT versus IMRT for the treatment of localized prostate cancer. J Radiat Oncol 2016;5:187–95.
[98]
Halpern JA, Sedrakyan A, Hsu WC, et al. Use, complications, and costs of stereotactic body radiotherapy for localized prostate cancer. Cancer 2016;122:2496–504.
[99]
Yu JB, Cramer LD, Herrin J, Soulos PR, Potosky AL, Gross CP. Stereotactic body radiation therapy versus intensity-modulated radiation therapy for prostate cancer: comparison of toxicity. J Clin Oncol 2014;32:1195–201.[100]
Hoppe BS, Michalski JM, Mendenhall NP, et al. Comparative effec- tiveness study of patient-reported outcomes after proton therapy or intensity-modulated radiotherapy for prostate cancer. Cancer 2014;120:1076–82.
[101]
Martin JM, Handorf EA, Kutikov A, et al. The rise and fall of prostate brachytherapy: use of brachytherapy for the treatment of local- ized prostate cancer in the National Cancer Data Base. Cancer 2014;120:2114–21.
[102]
Mahmood U, Pugh T, Frank S, et al. Declining use of brachytherapy for the treatment of prostate cancer. Brachytherapy 2014;13: 157–62.
[103]
Orio 3rd PF, Nguyen PL, Buzurovic I, Cail DW, Chen YW. The decreased use of brachytherapy boost for intermediate and high-risk prostate cancer despite evidence supporting its effec- tiveness. Brachytherapy 2016;15:701–6.
[104]
Morris WJ, Tyldesely S, Rodda S, et al. *ASCENDE-RT: An analysis of survival endpoints for a randomized trial comparing a low-dose- rate brachytherapy boost to a dose-escalated external beam boost for high- and intermediate-risk prostate cancer. Int J Radiat Oncol Biol Phys 2017;98:275–85.
[105]
Rodda SL, Tyldesely S, Morris WJ. Toxicity outcomes in ASCENDE- RT: a multicenter randomized trial of dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys 2015;93(3 Suppl): S121.
[106]
Rodda SL, Duncan G, Hamm J, Morris WJ. Quality of life outcomes: ASCENDE-RT a multicenter randomized trial of radiation therapy for prostate cancer. Int J Radiat Oncol Biol Phys 2015;93(3 Suppl): S2.E U R O P E A N U R O L O G Y 7 3 ( 2 0 1 8 ) 1 1 – 2 0
20